Romiplostim Research

Vecchio V, Markovic U, Grasso S, Nardo A, Giuffrida G

BACKGROUND This report describes the case of a 50-year-old White male who presented with primary immune thrombocytopenia (ITP). He had a history of a previous episode of cerebral ischemia 1year before ITP onset, and a smoking habit. The ITP outcome was characterized by bleeding and thrombosis. Bl...

Dainiak N, Akashi M, Chao N, Port M, Powles R, Sanchez U et al.

A WHO panel previously recommended the use of hematopoietic cytokines to manage H-ARS within 24 hours of exposure to ≥ 2 Gy radiation dose, a recommendation that has been endorsed by hematologists and oncologists with expertise in radiation management. Nevertheless, no state-of-the-art con...

Köseoğlu FD, Kum A

Almutairi S, Warsi A, Hejazi A, Melibari E, Jar R, Almutairi A et al.

Immune thrombocytopenia (ITP) is an acquired autoimmune disorder characterized by increased platelet destruction and impaired platelet production. While thrombopoietin receptor agonists (TPO-RAs), including romiplostim and eltrombopag, have significantly improved ITP management, some patients rem...

Bogis A, Pulver S, Charp P, Wills E, Kazzi Z, Buzzell J et al.

A nuclear detonation resulting in radiation exposure to a large population can cause acute radiation syndrome (ARS). Bone marrow colony stimulating factors (CSF), also known as cytokines, are FDA approved to treat hematopoietic-acute radiation syndrome (H-ARS). This review characterizes the use o...

Cheng Y, Wei J, Zhu F, Xuan L, Li Y, Meng L et al.

Koilpillai S, Altaf R, El Barche Palmera A, Hassanein H, Carlan SJ

BACKGROUND Philadelphia chromosome (Ph)-negative B-cell acute lymphoblastic leukemia (B-ALL) is usually treated with intensive chemotherapy, presenting challenges for Jehovah's Witness patients who refuse blood products due to religious beliefs. These regimens often lead to severe cytopenias that...

Joffe E, Epstein-Peterson Z, Falchi L, Noy A, Zelenetz AD, Owens C et al.

Background/Objectives: Intensive chemotherapy is the cornerstone of lymphoma treatment but often leads to severe chemotherapy-induced thrombocytopenia (sCIT), resulting in treatment delays, reduced dose intensity, and the need for transfusions. While granulocyte colony-stimulating factors (G-CSFs...

Grozovsky R, Fraser CS, Qin X, Spetz J, Sarosiek KA

Platelets are short-lived anucleate cells essential for primary hemostasis and recognized for their functions in thrombosis, immunity, antimicrobial defense, neurodegeneration, as well as cancer growth and metastasis. Their brief lifespan in circulation is controlled by the removal of sialic acid...

Karimizadeh Z, Behfar M, Karimzadeh A, Jafari L, Kalantari A, Nikfetrat Z et al.

Prolonged thrombocytopenia after hematopoietic stem cell transplantation (HSCT) in pediatric patients is associated with significant morbidity, including increased transfusion dependency, bleeding events, and reduced survival. Romiplostim (Nplate, Amgen), a thrombopoietin receptor agonist, has sh...

Hamidoglu H, Abu Tawileh R, Abouelkhel HN

The COVID-19 pandemic has significantly impacted global health since its emergence in late 2019. Established evidence indicates an increasing incidence of hematologic abnormalities caused by COVID-19, such as aplastic anemia. Only a few pediatric cases have been reported. We present a previously ...

Mingot-Castellano ME, Alcalde-Mellado P, Entrena-Ureña L, Pascual-Izquierdo C, Zafra-Torres D, Canaro Hirnyk M et al.

Multirefractory immune thrombocytopenia (ITP) is difficult to manage. The simultaneous administration of an immunosuppressive/immunomodulatory drug (IS/IM) and a thrombopoietin receptor agonist (TPO-RA) is increasingly used. We present the experience of the Spanish ITP Group in this retrospective...

Talreja V, Khatwani S, Subhagan P

Chemotherapy-induced thrombocytopenia (CIT) is a frequent complication of antineoplastic therapy. The incidence of CIT varies with cancer type and regimen used. CIT can result in chemotherapy delays, dose reductions, and discontinuation, leading to reduced survival rates· Romiplostim is a th...

Abu-Tineh M, Beereddy D, Saldivar Ruiz II, Samat D

Background: Evans syndrome is a rare autoimmune disease characterized by immune thrombocytopenia (ITP), autoimmune hemolytic anemia (AIHA), and autoimmune neutropenia, typically triggered by an episode of immune dysregulation or multiple other factors. We present what appears to be the first repo...

Fernández-Sánchez A, García-Jaén P, Puerta-Vázquez C, Pazmiño-Zambrano MB, Reguera-Puertas P, González-Porras JR et al.

Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for various malignancies, but they are associated with a range of immunerelated adverse events, including rare hematological complications. Immune thrombocytopenia (ITP) has been reported with other antiPD1 agents such a...

Yoon JH, Lee S, Kwag D, Min GJ, Park SS, Park S et al.

Thrombopoietin receptor agonists (TPO-RAs) have become a cornerstone in the management of relapsed or refractory immune thrombocytopenia (R/R-ITP), with emerging evidence supporting treatment discontinuation in selected patients. However, predictors of sustained response and real-world switching ...

Lai Y, Pan Q, Wang S, Luo Q, Huang Z, Wei M et al.

The objective of this study was to compare and rank the efficacy and safety of different thrombopoietin receptor agonists (TPO-RAs) in the treatment of chemotherapy-induced thrombocytopenia (CIT) among patients with solid tumors.PubMed, Cochrane Library, Embase, MEDLINE, Web of Science, ClinicalT...

Nelson VS, Smit ER, de Haas M, Schipperus MR, van den Biggelaar M, Kapur R et al.

Düzenli Kar Y, Sezgin Evim M, Mete UC, Ayyildiz Emecan D, Atik T, Meral Güneş A et al.

GNE mutations are rare pathologic conditions that can cause severe thrombocytopenia and bleeding tendency from the neonatal period. The clinical presentation of patients with GNE mutations varies from mild skin and mucosal bleeding to life-threatening bleeding.This study reported two siblings wit...

Yamaguchi M, Hirouchi T, Sato Y, Kashiwakura I

Environmental stressors, such as ionizing radiation, accelerate aging by causing DNA damage and triggering pathways that lead to cell cycle arrest, apoptosis, and subsequent inflammation. The thrombopoietin receptor agonist romiplostim (RP), which is used as a clinical treatment for chronic idiop...